25/100B40.640
USD
-0.02
(-0.05%)
Market Open
Last updated: · Delayed 15 min
Roivant Sciences total debt 2019–2026What is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
Roivant Sciences's total debt was 106.57M USD on 30 September 2026, up 7.8% on a year before. At the end of fiscal year 2025 it was 107.44M USD.
Last updated 10 Nov 2026 · Next report 5 Feb 2027
Total debt
Growth
| Fiscal year | Period ending | Total debt | Growth | Cash and short-term investments | Net cash | Debt to equity |
|---|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 106.57M | +7.81% | 4.21B | 4.10B | 0.02 |
| FY2025 | 31 Mar 2026 | 107.44M | +7.26% | 4.30B | 4.19B | 0.02 |
| FY2024 | 31 Mar 2025 | 100.17M | -79.96% | 4.89B | 4.79B | 0.02 |
| FY2023 | 31 Mar 2024 | 499.75M | +3.81% | 6.54B | 6.04B | 0.08 |
| FY2022 | 31 Mar 2023 | 481.40M | +69.57% | 1.68B | 1.20B | 0.42 |
| FY2021 | 31 Mar 2022 | 283.89M | +15.88% | 2.06B | 1.78B | 0.17 |
| FY2020 | 31 Mar 2021 | 244.98M | +35.43% | 2.13B | 1.89B | 0.13 |
| FY2019 | 31 Mar 2020 | 180.88M | — | 2.19B | 2.00B | 0.09 |
| Quarter | Period ending | Total debt | Growth on a year before | Cash and short-term investments | Net cash | Debt to equity |
|---|---|---|---|---|---|---|
| Q2 FY2026 | 30 Sept 2026 | 106.57M | +7.81% | 4.21B | 4.10B | 0.02 |
| Q1 FY2026 | 30 Jun 2026 | 107.15M | +7.48% | 3.84B | 3.73B | 0.03 |
| Q4 FY2025 | 31 Mar 2026 | 107.44M | +7.26% | 4.30B | 4.19B | 0.02 |
| Q3 FY2025 | 31 Dec 2025 | 207.44M | +106.79% | 4.53B | 4.32B | 0.05 |
| Q2 FY2025 | 30 Sept 2025 | 98.85M | +87.53% | 4.39B | 4.29B | 0.02 |
| Q1 FY2025 | 30 Jun 2025 | 99.69M | -73.70% | 4.50B | 4.40B | 0.02 |
| Q4 FY2024 | 31 Mar 2025 | 100.17M | -79.96% | 4.89B | 4.79B | 0.02 |
| Q3 FY2024 | 31 Dec 2024 | 100.31M | -80.20% | 5.15B | 5.05B | 0.02 |
| Q2 FY2024 | 17 Sept 2024 | 52.71M | -89.42% | 5.39B | 5.33B | 0.01 |
| Q1 FY2024 | 30 Jun 2024 | 379.06M | -23.06% | 5.68B | 5.30B | 0.07 |
| Q4 FY2023 | 31 Mar 2024 | 499.75M | +2.60% | 6.54B | 6.04B | 0.08 |
| Q3 FY2023 | 31 Dec 2023 | 506.58M | +5.62% | 6.67B | 6.16B | 0.08 |
| Q2 FY2023 | 30 Sept 2023 | 497.98M | — | 1.41B | 915.73M | 0.52 |
| Q1 FY2023 | 30 Jun 2023 | 492.64M | — | 1.44B | 946.72M | 0.54 |
| Q4 FY2022 | 31 Mar 2023 | 487.07M | — | 1.68B | 1.19B | 0.42 |
| Q3 FY2022 | 31 Dec 2022 | 479.64M | — | 1.53B | 1.05B | 0.50 |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
Total debt counts commercial paper, term debt and lease liabilities.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet
Common questions about Roivant Sciences's debt
Source: Financial Modeling Prep